文献速递胸部肿瘤消化系统肿瘤

NRG1融合驱动肿瘤:生物学、检测及阿法替尼等ErbB靶向治疗作用

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
PubMed 文献 · Ann Oncol · 2020-09-09

NRG1融合导致ErbB通路激活,是靶向治疗的合理候选。最常见为CD74-NRG1,多见于肺浸润性黏液腺癌(IMA)。NRG1融合在多数癌症中发生率<1%,但IMA中约10%-30%。阿法替尼等ErbB靶向治疗是潜在策略。

要点

  • NRG1融合通过ErbB通路激活驱动肿瘤,是靶向治疗候选。
  • CD74-NRG1最常见,多见于肺IMA,其他融合伴侣包括ATP1B1、SDC4、RBPMS。
  • NRG1融合总体罕见(<1%),但IMA中约10%-30%,约20%融合阳性NSCLC为非黏液腺癌。

核心结论

  • NRG1融合导致ErbB介导的通路激活,为靶向治疗提供合理候选。
  • 阿法替尼等ErbB靶向治疗是NRG1融合阳性患者满足未满足治疗需求的潜在策略。

研究设计与样本

  • 综述,总结NRG1融合的生物学、检测及ErbB靶向治疗作用。

主要发现

  • 最常见NRG1融合为CD74-NRG1,多见于肺浸润性黏液腺癌(IMA)。
  • 其他NRG1融合伴侣包括ATP1B1、SDC4和RBPMS,见于肺癌患者。
  • NRG1融合也见于其他实体瘤如胰腺导管腺癌。
  • NRG1融合在不同癌症中总体罕见,报告发生率<1%,但IMA例外。
  • IMA占肺腺癌约2%-10%,其NRG1融合报告发生率约10%-30%。

临床怎么用

  • 对肺IMA患者应考虑NRG1融合检测,因该亚型融合发生率较高。
  • NRG1融合阳性患者可考虑阿法替尼等ErbB靶向治疗作为潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oncogenic gene fusions are hybrid genes that result from structural DNA rearrangements, leading to deregulated activity. Fusions involving the neuregulin-1 gene (NRG1) result in ErbB-mediated pathway activation and therefore present a rational candidate for targeted treatment. The most frequently reported NRG1 fusion is CD74-NRG1, which most commonly occurs in patients with invasive mucinous adenocarcinomas (IMAs) of the lung, although several other NRG1 fusion partners have been identified in patients with lung cancer, including ATP1B1, SDC4, and RBPMS. NRG1 fusions are also present in patients with other solid tumors, such as pancreatic ductal adenocarcinoma. In general, NRG1 fusions are rare across different types of cancer, with a reported incidence of <1%, with the notable exception of IMA, which represents ≈2%-10% of lung adenocarcinomas and has a reported incidence of ≈10%-30% for NRG1 fusions. A substantial proportion (≈20%) of NRG1 fusion-positive non-small-cell lung cancer cases are nonmucinous adenocarcinomas. ErbB-targeted treatments, such as afatinib, a pan-ErbB tyrosine kinase inhibitor, are potential therapeutic strategies to address unmet treatment needs in patients harboring NRG1 fusions.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Laskin J, Liu SV, Tolba K, et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann Oncol. 2020. PMID: 32916265. doi:10.1016/j.annonc.2020.08.2335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。